{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T22:33:46Z","timestamp":1786660426083,"version":"build-2736575974"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2023,3,10]],"date-time":"2023-03-10T00:00:00Z","timestamp":1678406400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,5,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Standard once-daily dosing of ceftriaxone may not lead to adequate antibiotic exposure in all cases of Staphylococcus aureus bacteraemia (SAB). Therefore, we compared clinical effectiveness of empirical antibiotic treatment with flucloxacillin, cefuroxime and ceftriaxone in adult patients with MSSA bacteraemia<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We analysed data from the Improved Diagnostic Strategies in Staphylococcus aureus bacteraemia (IDISA) study, a multicentre prospective cohort study of adult patients with MSSA bacteraemia. Duration of bacteraemia and 30 day SAB-related mortality were compared between the three groups using multivariable mixed-effects Cox regression analyses.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In total, 268 patients with MSSA bacteraemia were included in the analyses. Median duration of empirical antibiotic therapy was 3 (IQR 2\u20133) days in the total study population. Median duration of bacteraemia was 1.0 (IQR 1.0\u20133.0) day in the flucloxacillin, cefuroxime and ceftriaxone groups. In multivariable analyses, neither cefuroxime nor ceftriaxone were associated with increased duration of bacteraemia (respectively HR 1.08, 95% CI 0.73\u20131.60 and HR 1.22, 95% CI 0.88\u20131.71) compared with flucloxacillin, nor were the cephalosporins associated with higher 30 day SAB-related mortality (respectively, subdistribution HR (sHR) 1.37, 95% CI 0.42\u20134.52 and sHR 1.93, 95% CI 0.67\u20135.60).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>In this study, we could not demonstrate a difference in duration of bacteraemia and 30 day SAB-related mortality between patients with SAB empirically treated with flucloxacillin, cefuroxime or ceftriaxone. Since sample size was limited, it is possible the study was underpowered to find a clinically relevant effect.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkad057","type":"journal-article","created":{"date-parts":[[2023,3,10]],"date-time":"2023-03-10T15:55:34Z","timestamp":1678463734000},"page":"1175-1181","source":"Crossref","is-referenced-by-count":8,"title":["Comparative effectiveness of \u03b2-lactams for empirical treatment of methicillin-susceptible <i>Staphylococcus aureus<\/i> bacteraemia: a prospective cohort study"],"prefix":"10.1093","volume":"78","author":[{"given":"D T P","family":"Buis","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Division of Infectious Diseases, Amsterdam Institute for Infection and Immunity, Amsterdam UMC, Vrije Universiteit Amsterdam , De Boelelaan 1117, Amsterdam , the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5873-0474","authenticated-orcid":false,"given":"T W","family":"van der Vaart","sequence":"additional","affiliation":[{"name":"Julius Center for Health Sciences and Primary Care, UMC Utrecht, Utrecht University , Utrecht , the Netherlands"},{"name":"Department of Internal Medicine, Division of Infectious Diseases, Amsterdam UMC, Universiteit van Amsterdam , Amsterdam , the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5415-8933","authenticated-orcid":false,"given":"J M","family":"Prins","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Infectious Diseases, Amsterdam Institute for Infection and Immunity, Amsterdam UMC, Vrije Universiteit Amsterdam , De Boelelaan 1117, Amsterdam , the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J T M","family":"van der Meer","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Infectious Diseases, Amsterdam UMC, Universiteit van Amsterdam , Amsterdam , the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M J M","family":"Bonten","sequence":"additional","affiliation":[{"name":"Julius Center for Health Sciences and Primary Care, UMC Utrecht, Utrecht University , Utrecht , the Netherlands"},{"name":"Department of Medical Microbiology, University Medical Centre Utrecht, Utrecht University , Utrecht , the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Sieswerda","sequence":"additional","affiliation":[{"name":"Julius Center for Health Sciences and Primary Care, UMC Utrecht, Utrecht University , Utrecht , the Netherlands"},{"name":"Department of Medical Microbiology, University Medical Centre Utrecht, Utrecht University , Utrecht , the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C H","family":"van Werkhoven","sequence":"additional","affiliation":[{"name":"Julius Center for Health Sciences and Primary Care, UMC Utrecht, Utrecht University , Utrecht , the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K C E","family":"Sigaloff","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Infectious Diseases, Amsterdam Institute for Infection and Immunity, Amsterdam UMC, Vrije Universiteit Amsterdam , De Boelelaan 1117, Amsterdam , the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,3,10]]},"reference":[{"key":"2023121114314451100_dkad057-B1","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1128\/CMR.05022-11","article-title":"Predictors of mortality in Staphylococcus aureus bacteremia","volume":"25","author":"van Hal","year":"2012","journal-title":"Clin Microbiol Rev"},{"key":"2023121114314451100_dkad057-B2","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1093\/jac\/dky120","article-title":"Limitations of ceftriaxone compared with cefazolin against MSSA: an integrated pharmacodynamic analysis","volume":"73","author":"Zelenitsky","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2023121114314451100_dkad057-B3","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1111\/j.1469-0691.2010.03425.x","article-title":"Are all beta-lactams similarly effective in the treatment of methicillin-sensitive Staphylococcus aureus bacteraemia?","volume":"17","author":"Paul","year":"2011","journal-title":"Clin Microbiol Infect"},{"key":"2023121114314451100_dkad057-B4","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1093\/jac\/dky071","article-title":"Pharmacokinetics and pharmacodynamic target attainment of ceftriaxone in adult severely ill sub-Saharan African patients: a population pharmacokinetic modelling study","volume":"73","author":"Bos","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2023121114314451100_dkad057-B5","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1093\/cid\/ciab632","article-title":"Prediction rules for ruling out endocarditis in patients with Staphylococcus aureus bacteremia","volume":"74","author":"van der Vaart","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2023121114314451100_dkad057-B6","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofac653","article-title":"All-cause and infection-related mortality in Staphylococcus aureus bacteraemia, a multicentre prospective cohort study","volume":"9","author":"van der Vaart","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"2023121114314451100_dkad057-B7","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/S1473-3099(20)30447-3","article-title":"Defining persistent Staphylococcus aureus bacteraemia: secondary analysis of a prospective cohort study","volume":"20","author":"Kuehl","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"2023121114314451100_dkad057-B8","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"2023121114314451100_dkad057-B9","doi-asserted-by":"crossref","first-page":"791","DOI":"10.7326\/0003-4819-137-10-200211190-00007","article-title":"Health care\u2013associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections","volume":"137","author":"Friedman","year":"2002","journal-title":"Ann Intern Med"},{"key":"2023121114314451100_dkad057-B10","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1097\/01.CCM.0000050454.01978.3B","article-title":"2001 SCCM\/ESICM\/ACCP\/ATS\/SIS international sepsis definitions conference","volume":"31","author":"Levy","year":"2003","journal-title":"Crit Care Med"},{"key":"2023121114314451100_dkad057-B11","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.jinf.2013.10.015","article-title":"Staphylococcus aureus bloodstream infection: a pooled analysis of five prospective, observational studies","volume":"68","author":"Kaasch","year":"2014","journal-title":"J Infect"},{"key":"2023121114314451100_dkad057-B12","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1086\/313753","article-title":"Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis","volume":"30","author":"Li","year":"2000","journal-title":"Clin Infect Dis"},{"key":"2023121114314451100_dkad057-B13","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Statist Assoc"},{"key":"2023121114314451100_dkad057-B14","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.01530-21","article-title":"Comparable effectiveness of cefuroxime and piperacillin-tazobactam as empirical therapy for methicillin-susceptible Staphylococcus aureus bacteremia","volume":"10","author":"Bigseth","year":"2022","journal-title":"Microbiol Spectr"},{"key":"2023121114314451100_dkad057-B15","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1093\/jac\/dkac152","article-title":"Empirical use of \u03b2-lactam\/\u03b2-lactamase inhibitor combinations does not increase mortality compared with cloxacillin and cefazolin in methicillin-susceptible Staphylococcus aureus bacteraemia: a propensity-weighted cohort study","volume":"77","author":"Willekens","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"2023121114314451100_dkad057-B16","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s12941-016-0143-3","article-title":"Comparative effectiveness of \u03b2-lactam versus vancomycin empiric therapy in patients with methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia","volume":"15","author":"Wong","year":"2016","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"2023121114314451100_dkad057-B17","author":"EUCAST","year":"2022"},{"key":"2023121114314451100_dkad057-B18","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2021.106486","article-title":"Ceftriaxone versus antistaphylococcal antibiotics for definitive treatment of methicillin-susceptible Staphylococcus aureus infections: a systematic review and meta-analysis","volume":"59","author":"Yetmar","year":"2022","journal-title":"Int J Antimicrob Agents"},{"key":"2023121114314451100_dkad057-B19","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofy089","article-title":"A comparison of cefazolin versus ceftriaxone for the treatment of methicillin-susceptible Staphylococcus aureus bacteremia in a tertiary care VA medical center","volume":"5","author":"Carr","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"2023121114314451100_dkad057-B20","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofaa341","article-title":"Outcomes of outpatient parenteral antimicrobial therapy with ceftriaxone for methicillin-susceptible Staphylococcus aureus bloodstream infections\u2014a single-center observational study","volume":"7","author":"Hamad","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"2023121114314451100_dkad057-B21","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1007\/s11096-014-9999-5","article-title":"Outcomes of ceftriaxone use compared to standard of therapy in methicillin susceptible staphylococcal aureus (MSSA) bloodstream infections","volume":"36","author":"Patel","year":"2014","journal-title":"Int J Clin Pharm"},{"key":"2023121114314451100_dkad057-B22","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0208819","article-title":"Time to positivity of blood cultures supports early re-evaluation of empiric broad-spectrum antimicrobial therapy","volume":"14","author":"Lambregts","year":"2019","journal-title":"PLoS One"},{"key":"2023121114314451100_dkad057-B23","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1186\/s12879-022-07653-3","article-title":"The 2021 Dutch working party on antibiotic policy (SWAB) guidelines for empirical antibacterial therapy of sepsis in adults","volume":"22","author":"Sieswerda","year":"2022","journal-title":"BMC Infect Dis"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/78\/5\/1175\/54253199\/dkad057.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/78\/5\/1175\/54253199\/dkad057.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,11]],"date-time":"2023-12-11T18:44:19Z","timestamp":1702320259000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/78\/5\/1175\/7075678"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,10]]},"references-count":23,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,3,10]]},"published-print":{"date-parts":[[2023,5,3]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkad057","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,5,3]]},"published":{"date-parts":[[2023,3,10]]}}}